Whitaker Myers Wealth Managers LTD. Boosts Holdings in Gilead Sciences, Inc. $GILD

Whitaker Myers Wealth Managers LTD. grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 27.0% in the second quarter, HoldingsChannel reports. The fund owned 18,284 shares of the biopharmaceutical company’s stock after buying an additional 3,890 shares during the quarter. Whitaker Myers Wealth Managers LTD.’s holdings in Gilead Sciences were worth $2,310,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Brighton Jones LLC increased its position in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC purchased a new position in Gilead Sciences during the fourth quarter worth approximately $215,000. Sivia Capital Partners LLC boosted its holdings in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 602 shares during the last quarter. Ieq Capital LLC boosted its holdings in shares of Gilead Sciences by 12.0% in the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after purchasing an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC grew its stake in shares of Gilead Sciences by 18.6% during the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock valued at $516,000 after buying an additional 674 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research analyst reports. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Daiwa Securities Group reduced their target price on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Truist Financial dropped their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Finally, Wall Street Zen downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $158.04.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead raised its 2026 base-business outlook, citing continued strength in its HIV portfolio and growing PrEP demand. Management also highlighted Trodelvy growth and two potential product launches in the second half of the year. GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
• Positive Sentiment: Second-quarter revenue of $7.80 billion exceeded expectations, and revenue increased 10.6% year over year. Although reported earnings were distorted by acquisition-related items, the underlying operating performance was viewed as stronger than the headline loss suggests. Gilead lifts sales outlook on strong Q2 HIV growth despite acquisition-related loss
• Positive Sentiment: Analysts at Cantor Fitzgerald and Needham & Company reiterated favorable views, assigning Gilead Overweight and Buy ratings, respectively. Gilead Sciences Earns Overweight Rating from Cantor Fitzgerald Gilead Sciences Earns Buy Rating from Needham
• Neutral Sentiment: Gilead’s research pipeline could provide longer-term growth, but investors are weighing whether development spending and potential launches can translate into sustainable commercial returns. Can Gilead Sciences Turn Research Into Growth?
• Neutral Sentiment: RBC raised its Gilead price target to $123, signaling a more constructive view, though the target remains below the reference market price and therefore offers limited near-term upside. RBC Increases Gilead Sciences Price Target
• Negative Sentiment: MSD and Gilead discontinued a Phase III Trodelvy-Keytruda study after lackluster interim data, weakening expectations for a major combination-therapy expansion of Trodelvy. MSD and Gilead scrap Phase III Trodelvy-Keytruda study

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the sale, the insider directly owned 125,779 shares in the company, valued at approximately $16,513,524.91. This trade represents a 18.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the sale, the chief financial officer owned 173,191 shares in the company, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 82,000 shares of company stock worth $10,641,790 over the last quarter. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $133.21 on Friday. The firm has a fifty day moving average of $129.41 and a 200-day moving average of $136.20. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.14 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $165.39 billion, a P/E ratio of -49.89 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same quarter in the previous year, the business posted $2.01 EPS. The business’s quarterly revenue was up 10.6% on a year-over-year basis. As a group, analysts predict that Gilead Sciences, Inc. will post -0.5 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.